Flatiron Health CEO and Co-Founder Nat Turner says one of the challenges facing the use of real-world data in a clinical trial setting is the significant amount of data required.
Turner made the comments during a videotaped interview with the American Journal of Managed Care.
The executive also weighed in on the Food and Drug Administration’s role in facilitating the use of RWD.
“Ultimately, real-world evidence is not really used for regulatory decisions right now, it’s more used for publications, supplemental data,” Turner said. “The FDA will have to be the one to ultimately say: hey we’re going to make a regulatory—maybe approve an expansion of a label, for example, that’s going to have to be them.”